Basel, 13 August 2018 FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies There are currently no FDA-approved treatments that help prevent severe reactions due to food allergies As many as 15 million Americans have food allergies – including approximately 6 million children – and the incidence is increasing Roche (SIX: RO, ROG;... Read more
Basel, 03 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting... Read more
Basel, 03 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting... Read more
Basel, 31 July 2018 Roche Purchases Shares in Tender Offer for FMI Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares... Read more
Basel, 31 July 2018 Roche Purchases Shares in Tender Offer for FMI Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares... Read more
Basel, 30 July 2018 Invitation to Roche’s Virtual Late Stage Pipeline Event 2018 We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Thursday, 13 September 2018, highlighting development and commercial opportunities within our late stage portfolio. We would like to invite all interested parties to... Read more
Basel, 27 July 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018,... Read more
Basel, 26 July 2018 Roche presents positive phase II results for the first-ever eye implant demonstrating sustained delivery of a biologic medicine to treat people with neovascular age-related macular degeneration Roche’s investigational Port Delivery System with ranibizumab (PDS) is intended to reduce the burden of frequent eye injections for people with neovascular age-related macular degeneration... Read more
Basel, 24 July 2018 Roche Analyst Event on Diagnostics Division at AACC 2018: Tuesday, 31st July, 6:00pm CDT Roche has held an analyst event on Tuesday, 31st July 2018 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 30-August... Read more
Basel, 23 July 2018 Roche receives CE Mark for its Accu-Chek Solo micropump system The Accu-Chek Solo micropump is a small, tube-free insulin delivery system that offers users the choice to bolus directly from the pump or from the fully-functional handheld as well as to detach and re-attach the pump without wasting insulin. The Accu-Chek... Read more